口服与静脉18F-NaF PET/CT在乳腺癌或前列腺癌骨转移评估中的比较
该前瞻性研究纳入36例乳腺癌(n=23)或前列腺癌(n=13)且骨转移高危患者,均先后接受静脉与口服18F-NaF PET/CT两项检查,间隔2至23天。分析134对病灶,静脉与口服途径的中位靶本比(TBR)分别为10.33与10.85,差异无统计学意义(P=0.212)。结论认为两种给药途径表现相当,静脉通路困难的患者可使用口服途径。
要点
- 口服与静脉18F-NaF PET/CT检测骨转移病灶的TBR无显著统计学差异(P=0.212)。
- 同一病灶两种途径TBR中位数:静脉10.33 vs 口服10.85。
- 观察者内与观察者间一致性均较好,加权κ最高为1.0。
核心结论
- 口服与静脉18F-NaF PET/CT给药途径表现相当,静脉通路困难的患者可使用口服途径。
研究设计与样本
- 前瞻性研究纳入36例乳腺癌(n=23)或前列腺癌(n=13)且骨转移高危患者,所有患者均接受静脉与口服18F-NaF PET/CT两项检查,间隔2至23天。
主要发现
- 共分析134对病灶,静脉与口服途径的中位TBR分别为10.33与10.85,差异无统计学意义(P=0.212)。
- 医师1的观察者内加权κ为1.0(95%CI 0.92-1.0),医师2为0.92(95%CI 0.81-0.99)。
- 观察者间系数在「口服 vs 口服」为0.82,在「静脉 vs 静脉」为0.87。
临床怎么用
- 作者认为,在静脉通路困难的患者中可使用口服18F-NaF PET/CT途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to compare oral and IV administrations of 18 F-NaF PET/CT for detection of suspicious bone metastatic lesions of breast and prostate cancers. PATIENTS AND METHODS: Thirty-six patients with breast (n = 23) or prostate (n = 13) cancers and high risk for bone metastases were prospectively evaluated. All patients underwent 2 PET/CT studies after IV and oral 18 F-NaF administration within a 2 to 23 days interval between them. The maximum SUVs from the same suspicious lesions (≤5 index lesions per patient) in both studies were measured. The target-to-background ratio (TBR), defined as the relation between the lesion maximum SUV and the whole skeletal mean SUV, was calculated for each lesion. The TBRs in the same lesion calculated using the 2 administration routes were compared. The agreements between 2 physicians in the definition of the number of lesions in both studies were also assessed using weighted κ. RESULTS: One hundred thirty-four pairs of lesions were analyzed. There was no significant statistical difference between the median TBRs ( P = 0.212) for IV (10.33) and oral (10.85). Excellent intraobserver agreement was observed between IV and oral routes: weighted κ of 1.0 (95% confidence interval, 0.92-1.0) and 0.92 (95% confidence interval, 0.81-0.99) for physicians 1 and 2, respectively. The interobserver coefficients were 0.82 and 0.87 for "oral versus oral" and "IV versus IV," respectively. CONCLUSIONS: 18 F-NaF PET/CT studies using oral and IV routes present comparable performance; thus, it is possible to use oral route in patients with difficult venous access.
引用
- Rocha NH, Zacchi SR, Sado HN, et al. Comparison of Oral and IV 18 F-NaF PET/CT Administration in the Assessment of Bone Metastases in Patients With Breast or Prostate Cancers. Clin Nucl Med. 2023. PMID: 37351903. doi:10.1097/RLU.0000000000004745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。